TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Dbv Technologies
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides

DBV Technologies announced the completion of the last patient visit in its phase 3 VITESSE clinical trial for the VIASKIN® Peanut patch, targeting children aged 4-7 with peanut allergies. The company remains on track to publish primary data in the fourth quarter of the year.

Insights
APOS   positive

Expanding infrastructure portfolio with significant investment in renewable energy project


DBVT   positive

The company completed a major milestone in its clinical trial, demonstrating progress towards developing a potential treatment for peanut allergies in children, with leadership expressing optimism about upcoming results